Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/imt-2020-0263 http://scihub22266oqcxt.onion/10.2217/imt-2020-0263 33557591!7871744!33557591     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunotherapy 2021 ; 13 (5): 397-407 Nephropedia Template TP {{tp|p=33557591|t=2021. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma |pdf=|usr=}}{{33557591}} gab.com Text Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma JO: Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33557591 #FOAvip Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 +/- 30 cut-off index) that of the PCP (36 +/- 8.5 cut-off index) and mean protein concentration was found to be 46 +/- 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT04521309). Twit Text FOAVip Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma ????Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=33557591 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33557591 #FOAvip English Wikipedia <ref>{{Cite pmid|33557591}}</ref> Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma #MMPMID33557591 Ali S; Uddin SM; Ali A; Anjum F; Ali R; Shalim E; Khan M; Ahmed I; M Muhaymin S; Bukhari U; Luxmi S; Khan AS; Quraishy S Immunotherapy 2021[Apr]; 13 (5): 397-407 PMID33557591show ga Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 +/- 30 cut-off index) that of the PCP (36 +/- 8.5 cut-off index) and mean protein concentration was found to be 46 +/- 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT04521309). |Antibodies, Viral/immunology/*isolation & purification/therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/*blood/therapy[MESH] |Caprylates/chemistry[MESH] |Chemical Fractionation[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Immunoglobulins, Intravenous/immunology/*isolation & purification/therapeutic use[MESH]Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin f(epmc).pdf DeepDyve Pubget Overpricing